Physician profile
Gregory Borg
NPI 1487761391
$1,942.91
in general payments reported to CMS, 2019-2025
14 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $75.65 · 2021: $192 · 2022: $414 · 2023: $245 · 2024: $445 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.49 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $525.13 | 2021-2025 | Nucala |
| Optinose US, INC. | $466.71 | 2019-2022 | |
| Genzyme Corporation | $387.32 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.61 | 2019-2024 | Dupixent |
| Intersect Ent, INC. | $84.26 | 2019-2021 | |
| Ambu INC. | $79.46 | 2022 | |
| Stryker Corporation | $46.84 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $20.80 | 2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals Lp | $20.23 | 2025 | Tezspire |
| Integra Lifesciences Corporation | $18.37 | 2022 | |
| Neurent Medical Limited | $15.58 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Medtronic, INC. | $15.33 | 2024 | Pteye Parathyroid Detection System |
| Arbor Pharmaceuticals, INC. | $12.92 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Borg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.